Abstract: Disclosed herein are anti-CTLA-4 antibodies possessing superior binding and biological activities relative to ipibmumab and tremelimumab, pharmaceutical compositions comprising such. Also provided herein are therapeutic and diagnostic applications of such anti-CTLA-4 antibodies.

Abstract: Disclosed herein are anti-CTLA-4 antibodies possessing superior binding and biological activities relative to ipibmumab and tremelimumab, pharmaceutical compositions comprising such. Also provided herein are therapeutic and diagnostic applications of such anti-CTLA-4 antibodies.

Abstract: A method and system for predicting subsequent cyber-attacks in attack campaigns are provided. The method includes receiving events data related to cyber-attacks occurring in a network during a predefined time window; extracting at least one sequence from the received events data at least one attack vector; generating a sequence signature for each of the at least one extracted sequence; comparing each sequence signature to a representation of historic sequence signatures to determine at least partially matching sequence signature; and based on the matching sequence, determining at least one subsequent cyber-attack in a respective sequence.

Abstract: A method and system for predicting subsequent cyber-attacks in attack campaigns are provided. The method includes receiving events data related to cyber-attacks occurring in a network during a predefined time window; extracting at least one sequence from the received events data at least one attack vector; generating a sequence signature for each of the at least one extracted sequence; comparing each sequence signature to a representation of historic sequence signatures to determine at least partially matching sequence signature; and based on the matching sequence, determining at least one subsequent cyber-attack in a respective sequence.

Abstract: A method of treating a disease in which inhibiting of a proteasome is advantageous is provided. The method comprises administering to the subject a therapeutically effective amount of a compound which binds to a proteasome of a cell, the compound comprising a copper bound to a ligand, the ligand being configured such that upon binding to the proteasome, the copper interacts with cysteine 31 of a Beta2 subunit of the proteasome and further interacts with cysteine 118 of a Beta3 subunit of the proteasome, thereby treating the disease. Additional novel proteasome inhibitors are also provided as well as methods of identifying proteasome inhibitors.

Abstract: A method of treating a disease in which inhibiting of a proteasome is advantageous is provided. The method comprises administering to the subject a therapeutically effective amount of a compound which binds to a proteasome of a cell, the compound comprising a copper bound to a ligand, the ligand being configured such that upon binding to the proteasome, the copper interacts with cysteine 31 of a Beta2 subunit of the proteasome and further interacts with cysteine 118 of a Beta3 subunit of the proteasome, thereby treating the disease. Additional novel proteasome inhibitors are also provided as well as methods of identifying proteasome inhibitors.

Abstract: One embodiment of the present invention provides a system for profiling a virtual machine on an embedded device. During operation, the system receives an operation-request at a system-level profiler from a virtual machine on an embedded device. The system then records the operation-request in a system-level log. Next, the system sends the operation-request to a native layer on the embedded device. Then, the system receives an operation-response associated with the operation-request from the native layer. The system then records the operation-response in the system-level log. Next, the system sends the operation-response to the virtual machine, thereby facilitating logging of interactions between the virtual machine and the native layer. Note that logging interactions between the virtual machine and the native layer facilitates emulation of the platform independent virtual machine on a second device.

Abstract: One embodiment of the present invention provides a system for testing an application running on a virtual machine. Note that this involves the system profiling the application, and determining when the virtual machine is executing code in response to commands from the application and when a device hosting the virtual machine is executing code in response to commands from the virtual machine. During operation, the system executes the application. In response to executing the application, the system receives a code-level log associated with the application from a code-level profiler. Then, using a system-level profiler, the system creates a system-level log associated with the application. Next, the system combines the code-level log and the system-level log to produce a profile of the application. The system then analyzes the profile to determine if a problem exists in the application.

Abstract: A method of diagnosing a disease in a subject in need thereof is disclosed. The method comprises: (a) linking a plurality of non-contiguous DNA fragments from a sample of the subject to generate a polynucleotide product, the linking being effected by contacting the plurality of non-contiguous DNA fragments with a multiplex overlap-extension primer mix under conditions that allow simultaneous linkage of the DNA fragments and amplification of the polynucleotide product, wherein the primer mix comprises two flanking primers and at least one linker primer; and (b) determining a sequence of the polynucleotide product, wherein the sequence is indicative of the disease.

Abstract: A method of treating a disease in which inhibiting of a proteasome is advantageous is provided. The method comprises administering to the subject a therapeutically effective amount of a compound which binds to a proteasome of a cell, the compound comprising a copper bound to a ligand, the ligand being configured such that upon binding to the proteasome, the copper interacts with cysteine 31 of a Beta2 subunit of the proteasome and further interacts with cysteine 118 of a Beta3 subunit of the proteasome, thereby treating the disease. Additional novel proteasome inhibitors are also provided as well as methods of identifying proteasome inhibitors.